SAN DIEGO, February 21, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced four presentations at upcoming healthcare events. ViaCyte is advancing two novel cell replacement therapies as long-term diabetes treatments. ViaCyte’s product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.
Details of the presentations are as follows:
Event: American Society of Transplantation – Cutting Edge of Transplantation Pipeline Session
Speaker: Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer
Date/Time: February 23, 10:00 AM MST
Location: Arizona Biltmore, Phoenix
Event: Keystone Engineered Cells and Tissues as Platforms for Discovery and Therapy
Speaker: Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer
Date/Time: March 9, 8:30 AM EST
Location: Fairmont Copley Plaza, Boston
Event: Center for Cell & Gene Therapy Series at Baylor College of Medicine
Speaker: Dr. Kevin D’Amour, Vice President, Research and Chief Scientific Officer
Date/Time: April 4, 9:00 AM EST
Location: Baylor College of Medicine, Houston
Event: GTCbio 14th Stem Cell Research & Regenerative Medicine Summit
Speaker: Dr. Mark Zimmerman, Vice President, Strategy and Business Development
Date/Time: April 6, 8:30 AM EST
Location: Hyatt Regency, Boston
